Skip to main content

Advertisement

Table 3 Changes in glycemic parameters from baseline to week 76

From: The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

  SAXA 2.5 mg q.A.M. (n = 74) SAXA 5 mg q.A.M. (n = 74) SAXA 2.5/5 mg q.A.M. (n = 71) SAXA 5 mg q.P.M. (n = 72) Control (n = 74)
HbA 1c (%) (repeated measures analysis)
BL, n 67 69 69 70 68
n with observed data at 76 weeks 24 34 28 26 31
BL, mean (SE) 8.0 (0.11) 7.9 (0.11) 8.0 (0.13) 7.9 (0.11) 7.8 (0.11)
Adj mean change from BL, mean (SE) −0.84 (0.122) −0.41 (0.108) −0.60 (0.118) −0.34 (0.117) −0.29 (0.114)
95% CI (−1.07, –0.60) (−0.63, –0.20) (−0.83, –0.37) (−0.57, –0.12) (−0.52, –0.07)
FPG (mg/dL) (repeated measures analysis)*
BL, n 70 71 71 71 72
n with observed data at 76 weeks 20 28 22 23 26
BL, mean (SE) 157 (4.0) 162 (4.2) 171 (6.2) 160 (5.3) 160 (5.5)
Adj mean change from BL, mean (SE) −12 (5.0) −1 (4.4) −15 (4.9) 1 (4.8) 0.1 (4.6)
95% CI (−21.8, –2.1) (−10.1, 7.3) (−24.0, –4.9) (−8.4, 10.3) (−9.0, 9.1)
HbA 1c <7.0% (LOCF)
N 67 69 69 70 68
n (%) 27 (40.3) 22 (31.9) 30 (43.5) 22 (31.4) 23 (33.8)
95% CI (28.5, 53.0) (21.2, 44.2) (31.6, 56.0) (20.9, 43.6) (22.8, 46.3)
PPG–AUC (mg·min/dL) (repeated measures analysis)*
BL, n 44 43 41 39 41
n with observed data at 76 weeks 30 35 27 29 33
BL, mean (SE) 47053 (1529.8) 49512 (1621.9) 48084 (1673.4) 44498 (1813.4) 46111 (1938.3)
Adj mean change from BL, mean (SE) −5859 (1498.3) −4163 (1429.2) −8511 (1571.7) −4700 (1547.4) −3788 (1465.6)
95% CI (−8821, –2897) (−6988, –1338) (−11618, –5404) (−7759, –1642) (−6685, –891)
  1. *Value rounded to nearest whole number
  2. Adj: adjusted; BL: baseline; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; LOCF: last observation carried forward; PPG–AUC: postprandial glucose-area under the curve; SAXA: saxagliptin; SE: standard error